Creaticon
Implementing Immunodiagnostic Tests for Effective Treatment

Numerous diagnostic procedures are available to determine blood medication concentrations as well as the presence of viral, endocrine, and neoplastic disorders. However, traditional diagnostic tests such as imaging techniques, biopsies, blood tests, and endoscopy are not as effective as immunodiagnostic tests. These tests offer many advantages over traditional methods as they are highly sensitive, specific, practical, and cost-effective. They find applications in drug development, biomedical research, and medical diagnostics. In addition, they provide important information on disease progression and can be used to treat cancer, hormonal problems, autoimmune and infectious diseases, and more. They can also aid in early cancer detection through biomarker identification and screening programs, leading to better treatment outcomes and reducing the need for more invasive interventions.

Creaticon Biotechnology Inc. specializes in immunodiagnostic tests, focusing on respiratory diseases, GI disorders, proteome, and proteome-specific biomarkers for diagnosis and early discovery of cancer. Using immunodiagnostic test proteins as the final target, Creaticon eliminates the lengthy waiting time and psychological stress associated with traditional tumor cell proliferation analysis. Instead, it provides rapid and accurate results, revolutionizing perceptions of cancer tests. Dr. Arthur Yi, general manager of Creaticon, states that their goal is to release reliable, secure, and accurate cancer tests in the global market, enabling people to lead healthy lives and cherish every precious moment.

In addition to cancer tests, Creaticon offers rapid tests for infectious diseases, over-the-counter (OTC) home tests, and under its consumer brand, Cogent. These rapid tests enhance accuracy, reduce screening time, and increase the number of early screenings, allowing for efficient health management. Creaticon is also developing a new product to detect the Helicobacter pylori bacteria in the GI tract, the primary cause of stomach cancer.

Clinical studies have demonstrated that Creaticon's products successfully detect infected individuals even with low viral loads. These tests are simple to use, ensuring accurate interpretation of results. While the available infectious disease tests are currently in the regulatory phase and intended for specialists, Creaticon aspires to create products the general public can purchase at pharmacies and perform tests at home. This approach minimizes the chance of community spread in areas with limited medical resources and reduces the time required for treatment, benefiting individuals with busy lifestyles.

Creaticon is researching and developing reliable, secure, and accurate cancer tests through rigorous scientific research in an effort to revolutionize perceptions of cancer tests and will be released in the global market as soon as they are produced

To maintain the safety and quality of its goods and services, Creaticon follows strict regulations for research and development, testing, clinical research, and production. The company operates a high-quality lab with ISO 13485 certification from the British Standards Institution (BSI), guaranteeing compliance with medical industry standards and customer requirements. Apart from that, Creaticon holds a quality manufacturer system certificate from the Taiwan Food and Drug Administration (TFDA).

Creaticon's ultimate objective is to promote accessible, accurate, quick, affordable, and user-friendly disease testing worldwide, allowing more people to benefit from advanced medical diagnostics.